Another Candidate For Novartis' Future Blockbuster Club Is Here.Friday, The Swiss Drugmaker Won Fda Approval For Adakveo, The First Targeted Therapy To Prevent The Painful Vaso-Occlusive Crises (Vocs) That Come Along With Sickle Cell Disease. The Nod Came Weeks Ahead Of Schedule, Even On Top Of A Priority Review Doled Out In July.Novartis Has Priced The New Drug, Meant For Patients 16 And Older, At A Wholesale Acquisition Cost (Wac) Of $2,357 Per Vial. As It
